Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 106.47$. Average daily volumn in 3 months 1.67M. Market cap 226.77B

Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 100.14$. Total volume : 1.13M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price

Previous Close99.36
Day Range99.61-100.92
Bid100.36 x 1.4k
Ask100.40 x 1.8k
Average Volume1.67M
Market Cap226.77B
52 Week Range91.51-122.16
Trailing P/E34.29
Foward P/E27.21
Dividend (Yield %)1.63%
Ex-Dividend Date2022-08-12

Financial Details

According to Novo Nordisk A/S's financial reports the company's revenue in 2021 were 140.8B an increase( +11.11%) over the years 2020 revenue that were of 126.95B. In 2021 the company's total earnings were 47.76B while total earnings in 2020 were 42.14B( +11.9%).

Loading ...


Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Market Cap:
Total Assets:
Total Cash:

News about "Novo Nordisk A/S"


Novo Nordisk A/S โ€“ Share repurchase programme

Source from : Yahoo - 3 days ago

On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»


Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug

Source from : MedCity News - 9 hours ago

Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule ...See details»


Montrealโ€™s Ventus Therapeutics strikes US$700-million-plus deal with pharma giant Novo Nordisk

Source from : The Globe and Mail - 17 hours ago

Montreal biotechnology company Ventus Therapeutics Inc. has struck a development and licensing deal with pharma giant Novo Nordisk A/S NVO-N that could be worth more than US$700-million ($960-million) ...See details»


Allworth Financial LP Acquires 138 Shares of Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 1 days ago

Allworth Financial LP grew its stake in shares of Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 34.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange ...See details»


HB Wealth Management LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 2 days ago

HB Wealth Management LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 22.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional ...See details»


Ventus sells its lead drug candidate to Novo Nordisk

Source from : BioPharma Dive - 13 hours ago

The biotechnology startup will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordiskโ€™s bet on inflammasome treatments.See details»


Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Source from : YAHOO!Finance - 14 hours ago

Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a ...See details»


Ventus Therapeutics cuts $70m deal with Danish drug giant Novo Nordisk

Source from : The Boston Globe on MSN - 15 hours ago

The local company is working on drugs to treat conditions such as nonalcoholic fatty liver disease and chronic kidney disease.See details»


Ominous Death Cross Forms On Novo Nordisk's Chart

Source from : on MSN - 3 days ago

If history is any guide, there may be trouble ahead for shares of Novo Nordisk (NYSE:NVO). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.See details»


Foundation behind Novo Nordisk to invest $200M in building quantum research โ€˜powerhouseโ€™

Source from : BioPharma Dive - 8 days ago

The grant is one of the Novo Nordisk Foundationโ€™s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.See details»


Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research

Source from : labiotech - 7 days ago

The Novo Nordisk Foundation has awarded a $200M grant for the first full-scale quantum computer to develop new medicines.See details»


Prothena: Paying A Premium To Cover All The Alzheimer's Bases

Source from : Seeking Alpha - 8 hours ago

Prothena's share price returns are dictated by the progress of other companies further advanced in the drug development process. Read why I give PRTA a hold rating.See details»

Novo Nordisk and Octagon Therapeutics Enter Inflammatory Disease Research Collaboration

Source from : PharmTech - 1 days ago

The collaboration will use Octagonโ€™s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise. Octagon Therapeutics, a ...See details»

Q&A: Novo Nordiskโ€™s Keith Middleton on its latest DE&I efforts

Source from : MM&M - 7 days ago

How is Novo Nordisk differentiating what itโ€™s doing compared to other players in the space? Middleton: The fact that we work in the therapeutic areas of the diseases that we do, it highlights a huge ...See details»